🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 17 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 07/08/2000 | 60,00 | 60,63 | 57,00 | 60,34 | +2,93% | 6,04% | 1.617.800 |
| 04/08/2000 | 53,88 | 59,50 | 53,53 | 58,63 | +13,22% | 11,08% | 1.100.000 |
| 03/08/2000 | 48,44 | 52,75 | 46,00 | 51,78 | +3,05% | 13,94% | 927.800 |
| 02/08/2000 | 53,13 | 56,50 | 50,00 | 50,25 | -4,46% | 12,24% | 473.400 |
| 01/08/2000 | 48,73 | 54,34 | 47,25 | 52,59 | +7,40% | 14,56% | 1.359.800 |
| 31/07/2000 | 50,06 | 50,31 | 46,88 | 48,97 | -0,95% | 6,87% | 344.200 |
| 28/07/2000 | 52,75 | 53,00 | 49,25 | 49,44 | -7,54% | 7,11% | 387.000 |
| 27/07/2000 | 54,50 | 54,50 | 52,00 | 53,47 | -0,98% | 4,59% | 648.400 |
| 26/07/2000 | 54,03 | 55,44 | 50,75 | 54,00 | -1,71% | 8,68% | 1.212.800 |
| 25/07/2000 | 57,94 | 58,38 | 54,31 | 54,94 | -4,61% | 7,01% | 859.400 |
| 24/07/2000 | 60,66 | 61,38 | 53,69 | 57,59 | -4,16% | 12,67% | 912.000 |
| 21/07/2000 | 59,56 | 63,44 | 58,94 | 60,09 | +1,42% | 7,56% | 1.187.000 |
| 20/07/2000 | 58,38 | 60,41 | 57,00 | 59,25 | +2,32% | 5,84% | 932.600 |
| 19/07/2000 | 61,56 | 61,69 | 57,53 | 57,91 | -5,56% | 6,75% | 436.800 |
| 18/07/2000 | 60,06 | 63,44 | 59,75 | 61,31 | +1,92% | 6,14% | 783.800 |
| 17/07/2000 | 59,50 | 61,00 | 58,59 | 60,16 | +4,62% | 4,04% | 1.047.000 |
| 14/07/2000 | 59,34 | 60,75 | 56,16 | 57,50 | -2,54% | 7,74% | 1.297.000 |
| 13/07/2000 | 63,72 | 63,84 | 57,75 | 59,00 | -7,00% | 9,56% | 939.600 |
| 12/07/2000 | 65,19 | 66,38 | 62,81 | 63,44 | +1,05% | 5,47% | 1.419.000 |
| 11/07/2000 | 59,38 | 65,31 | 59,38 | 62,78 | +4,53% | 10,00% | 2.448.400 |
| 10/07/2000 | 61,81 | 61,88 | 59,63 | 60,06 | -2,68% | 3,64% | 1.254.200 |
| 07/07/2000 | 61,69 | 62,38 | 58,50 | 61,72 | +4,55% | 6,28% | 2.826.000 |
| 06/07/2000 | 59,53 | 61,25 | 56,25 | 59,03 | -1,10% | 8,40% | 1.815.600 |
| 05/07/2000 | 53,75 | 60,38 | 52,06 | 59,69 | +10,53% | 15,47% | 2.176.600 |
| 03/07/2000 | 52,53 | 54,00 | 52,50 | 54,00 | +2,49% | 2,86% | 310.800 |
| 30/06/2000 | 53,45 | 53,53 | 48,13 | 52,69 | -3,66% | 10,11% | 2.393.800 |
| 29/06/2000 | 53,70 | 56,25 | 52,63 | 54,69 | -0,91% | 6,75% | 1.001.200 |
| 28/06/2000 | 54,69 | 55,41 | 54,00 | 55,19 | +1,73% | 2,57% | 1.086.400 |
| 27/06/2000 | 54,72 | 58,00 | 51,50 | 54,25 | -0,74% | 11,88% | 2.944.800 |
| 26/06/2000 | 48,81 | 55,00 | 48,63 | 54,66 | +12,84% | 13,06% | 1.851.800 |